COM-701 is a Monoclonal Antibody owned by Compugen, and is involved in 3 clinical trials, which are ongoing.

COM-701 inhibits the activity PVRIG. PVRIG induces T cell activation, with long term activation leading to the highest expression. PVRL2 was identified as the ligand for PVRIG, placing PVRIG in the DNAM/TIGIT immunoreceptor axis. The drug candidate disrupts the interaction of PVRIG with PVRL2 and enhances CD8 T cell proliferation and IFN-g production resulting in an additive or synergistic effect on T cell activation and thereby reduces the growth of tumors.

The revenue for COM-701 is expected to reach a total of $537m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the COM-701 NPV Report.

COM-701 is originated and owned by Compugen.

COM-701 Overview

COM-701 is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, multiple myeloma, PD1 refractory or relapsing head and neck squamous cell carcinoma including oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal, non-small cell lung cancer, colorectal cancer, endometrial cancer, primary peritoneal cancer and fallopian tube cancer. The drug candidate is a high affinity humanized IgG4 mAb. It is administered intravenously. It acts by targeting CGEN-15029/PVRIG, a B7/CD28 like immune checkpoint protein. The drug candidate is developed based on antibody therapeutic targets discovery platform and protein family members discovery platform.

Compugen Overview

Compugen is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s pipeline comprises COM701 and PVRIG, BAY 1905254, COM902, and TIGIT. Its drug development process includes target discovery, target validation, and predictive discovery programs. The company offers predictive theories for the integration process containing biology knowledge, genome, and proteome analysis and experimental and disease data, computational models, and novel and non-novel candidates. It has a presence in Israel, the US, and Canada. Compugen is headquartered in Holon, Tel Aviv, Israel.

The company reported revenues of (US Dollars) US$6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$2 million in FY2020. The operating loss of the company was US$35.1 million in FY2021, compared to an operating loss of US$31.5 million in FY2020. The net loss of the company was US$34.2 million in FY2021, compared to a net loss of US$29.7 million in FY2020.

Quick View – COM-701

Report Segments
  • Innovator
Drug Name
  • COM-701
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.